Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huzhangxiefei Decoction for Sepsis Induced Acute Lung Injury
NCT04940676Phase 2Unknown
- Sponsor
- Xinhua Hospital
- Start
- Mar 2021
- Primary completion
- Nov 2022
- Modality
- HM (Herbal Medicine), Dietary Supplement, NPI (Non-Pharmacological Intervention)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sepsis and acute lung injury (ALI) comparing Huzhangxiefei Decoction with Placebo (2 arms). Primary endpoints: Sequential Organ Failure Assessment Score at 7 days, C-Reactive Protein at 168 hours and 2 more. Status: unknown.
02
Drugs
huzhangxiefei decoction
03
Conditions
sepsisacute lung injury (ALI)
Beyond the preview
Go deeper on NCT04940676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940676.